WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Permanent URI for this collectionhttps://hdl.handle.net/11147/7150
Browse
15 results
Search Results
Now showing 1 - 10 of 15
Conference Object The Impact of Nutritional Ketosis on Autophagy in the Brain of Tay-Sachs Mouse Model(Springernature, 2024) Inci, Orhan Kerim; Seyrantepe, VolkanConference Object Investigation of the Regulatory Role of Lysosomal Cathepsin a in the Autophagy(Springernature, 2024) Yanbul, Selman; Seyrantepe, VolkanConference Object Therapeutic Efficacy of Intrathecal Administration of Aavrh10-Mhexa Vector in a Mouse Model of Tay-Sachs Disease(Springernature, 2024) Ozgur, Melike Can; Basirli, Hatice Hande; Ausseil, Jerome; Seyrantepe, VolkanArticle Citation - WoS: 1Citation - Scopus: 1Abnormally Accumulated Gm2 Ganglioside Contributes To Skeletal Deformity in Tay-Sachs Mice(Springer Heidelberg, 2024) Demir, Secil Akyildiz; Seyrantepe, VolkanTay-Sachs Disease is a rare lysosomal storage disorder caused by mutations in the HEXA gene, responsible for the degradation of ganglioside GM2. In addition to progressive neurodegeneration, Tay-Sachs patients display bone anomalies, including kyphosis. Tay-Sachs disease mouse model (Hexa-/-Neu3-/-) shows both neuropathological and clinical abnormalities of the infantile-onset disease phenotype. In this study, we investigated the effects of GM2 accumulation on bone remodeling activity. Here, we evaluated the bone phenotype of 5-month-old Hexa-/-Neu3-/- mice with age-matched control groups using gene expression analysis, bone plasma biomarker analysis, and micro-computed tomography. We demonstrated lower plasma alkaline phosphatase activity and calcium levels with increased tartrate-resistant acid phosphatase levels, indicating reduced bone remodeling activity in mice. Consistently, gene expression analysis confirmed osteoblast reduction and osteoclast induction in the femur of mice. Micro-computed tomography and analysis show reduced trabecular bone volume, mineral density, number, and thickness in Hexa-/-Neu3-/- mice. In conclusion, we demonstrated that abnormal GM2 ganglioside accumulation significantly triggers skeletal abnormality in Tay-Sachs mice. We suggest that further investigation of the molecular basis of bone structure anomalies is necessary to elucidate new therapeutic targets that prevent the progression of bone symptoms and improve the life standards of Tay-Sachs patients.Conference Object L-Arginine Treatment Corrects Impaired Autophagy in Gm2 Gangliosidosis Ab-Variant Mouse Cells(Wiley, 2024) Inci, Orhan Kerim; Ates, Nurselin; Seyrantepe, Volkan[No Abstract Available]Conference Object Treatment With Recombinant Human Lysosomal Sshexosaminidase Reduces Gm2 Accumulation in Tay-Sachs Disease Cells(Academic Press inc Elsevier Science, 2024) Inci, Orhan Kerim; Leal, Andres F.; Ates, Nurselin; Suarez, Diego; Espejo, Angela J.; Almeciga-Diaz, Carlos Javier; Seyrantepe, Volkan[No Abstract Available]Conference Object Investigating the Efficacy of Combined Ketogenic Diet and Anti-Inflammatory Therapy in a Mouse Model of Early-Onset Tay-Sachs Disease(SPRINGERNATURE, 2023) İnci, Orhan K.; Seyrantepe, VolkanReview Citation - WoS: 6Citation - Scopus: 8Molecular Trojan Horses for Treating Lysosomal Storage Diseases(Academic Press, 2023) Leal, Andres Felipe; Rintz, Estera; Çelik, Betül; Ago, Yasuhiko; León, Daniel; İnci, Orhan Kerim; Seyrantepe, VolkanLysosomal storage diseases (LSDs) are caused by monogenic mutations in genes encoding for proteins related to the lysosomal function. Lysosome plays critical roles in molecule degradation and cell signaling through interplay with many other cell organelles, such as mitochondria, endoplasmic reticulum, and peroxisomes. Even though several strategies (i.e., protein replacement and gene therapy) have been attempted for LSDs with promising results, there are still some challenges when hard-to-treat tissues such as bone (i.e., cartilages, ligaments, meniscus, etc.), the central nervous system (mostly neurons), and the eye (i.e., cornea, retina) are affected. Consistently, searching for novel strategies to reach those tissues remains a priority. Molecular Trojan Horses have been well-recognized as a potential alternative in several pathological scenarios for drug delivery, including LSDs. Even though molecular Trojan Horses refer to genetically engineered proteins to overcome the blood-brain barrier, such strategy can be extended to strategies able to transport and deliver drugs to specific tissues or cells using cell-penetrating peptides, monoclonal antibodies, vesicles, extracellular vesicles, and patient-derived cells. Only some of those platforms have been attempted in LSDs. In this paper, we review the most recent efforts to develop molecular Trojan Horses and discuss how this strategy could be implemented to enhance the current efficacy of strategies such as protein replacement and gene therapy in the context of LSDs. © 2023Conference Object Elimination of the B4galnt1 Gene Normalizes Lifespan and Prevents Pathology in Tay-Sachs Disease Mice(Elsevier, 2023) Seyrantepe, VolkanTay-Sachs disease is a neurodegenerative lysosomal storage disorder caused by mutations in the Hexa gene, which encodes the alpha subunit of lysosomal ß-hexaminidase A (HEXA). HEXA is responsible for the conversion of GM2 to GM3, therefore the deficiency leads to the accumulation of GM2 in the lysosomes, neurodegeneration, and eventual death. Currently, there is no efficient therapy for the disease yet.Conference Object Brain Lipid Profile of Early Onset Tay-Sachs Disease Mouse Model(Springernature, 2020) Şengül, Tuğçe; Can, Melike; Akyıldız Demir, Seçil; Klose, C.; Surma, M.; Seyrantepe, Volkan[Abstract Not Available]